Evotec SE (EVO) EPS (Weighted Average and Diluted) (2020 - 2021)
Evotec SE's (EVO) quarterly EPS (Weighted Average and Diluted) came in at $89.51 in Q3 2021, up 353.94% year-on-year from $19.72 in Q3 2020, and up 10191.54% quarter-over-quarter from $0.87 in Q2 2021.
Evotec SE (EVO) EPS (Weighted Average and Diluted) (2020 - 2021) Analysis & Trends
Evotec SE has disclosed EPS (Weighted Average and Diluted) across 2 years of filings, most recently posting $89.51 for Q3 2021.
- EPS (Weighted Average and Diluted) for Q3 2021 came in at $89.51, up 353.94% year-over-year; the trailing twelve-month figure through Sep 2021 was $89.51 (up 353.94% YoY), and the FY2025 annual result was -$0.68, up 43.08% from the prior year.
- EPS (Weighted Average and Diluted) came in at $89.51 for Q3 2021 at Evotec SE, up from $0.87 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $89.51 in Q3 2021 to a low of -$35.25 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 0.31 |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 1.42 |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 5.82 |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 0.02 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.91 |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 0.11 |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -0.40 |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -0.40 |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.80 |
| 10 | Evotec SE | 570.60 Mn | 570.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 89.51 |
| Jun 30, 2021 | 0.87 |
| Sep 30, 2020 | -35.25 |